Caplin Point Laboratories, a Pharmaceutical Public Limited Company headquartered in Chennai, manufacturing a wide range of Pharmaceutical Formulations, announced that Caplin Steriles Limited (a Subsidiary of Caplin Point Laboratories Ltd) has entered into a private label distribution agreement with Xellia Pharmaceuticals for five generic injectable ANDAs in the US.
The first product is expected to be launched shortly, while approvals for the remaining are expected in the next 12-18 months, Caplin said in its press statement.
Commenting on the transaction, C C Paarthipan, Chairman, Caplin Point Laboratories Limited, said: “We’re happy to announce this partnership with Xellia, a company with a long standing track record of commercial success in the US for injectable products. These ANDAs are under Caplin Steriles name and Xellia will be commercializing them in the US.”
Peter Karas, Xellia’s Vice President Global Business Development added “Xellia is excited to partner with Caplin Steriles on this portfolio of products as we continue to expand our injectable portfolio and commercial presence in the US market. Caplin Steriles’ focus on these essential medicines and their robust supply chain fits well with our track record of providing a consistent supply and growing list of essential medicines to patients in the US.”
Caplin Point Laboratories Limited is a fast growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point Laboratories Limited has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company has also entered regulated markets such as US through its Subsidiary Caplin Steriles Limited.
Caplin Point has been selected on Forbes Asia’s “200 Best Under a Billion” list for three consecutive years (2014, 2015 & 2016), and was recently awarded “The Emerging Company of 2018” by Economic Times Family Business Awards.
Xellia Pharmaceuticals is a specialty pharmaceutical company developing, manufacturing and commercializing anti-infective treatments against serious and often life-threatening bacterial and fungal infections.
With over 115 years of experience, Xellia is a world-leading trusted supplier of several important established anti-infective drugs, comprising active pharmaceutical ingredients as well as injectable products. Headquartered in Copenhagen, Denmark, Xellia has a global footprint with R&D, manufacturing and commercial operations across Europe, Asia, the Middle East and North America and is investing significantly to expand its sales and manufacturing capabilities within the United States. Xellia is wholly owned by Novo Holdings A/S and employs a dedicated team of over 1,800 people.
HrNxt.com Newsdesk has researchers and writers with an excellent domain knowledge about the talent ecosystem, and the business environment. The team keeps a tab on the latest happenings in the ecosystem to bring most relevant news and insights for our readers. You can connect with our newsdesk at newsdesk@hrnxt.com.